Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT study of BL-8040 and pembrolizumab in metastatic pancreatic adenocarcinoma
2018-004372-36Phase 2Completed
- Sponsor
- BioLineRx Ltd.
- Start
- May 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of motixafortide, pembrolizumab, irinotecan, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by BioLineRx Ltd. Primary endpoint: Objective Response Rate (RECIST 1.1). Started May 2019; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-004372-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004372-36.